References
- Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet. 2011;377(9773):1276–1287.
- Prevention D, on Osteoporosis NCDP. Osteoporosis prevention, diagnosis, and therapy. Jama. 2001;285(6):785–795.
- Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med. 2007;357(9):905–916.
- Tsujimoto M, Uenaka K, Iwata A, et al. Effects of teriparatide in Japanese and non-Japanese populations: bridging findings on pharmacokinetics and efficacy. J Bone Miner Metab. 2012;30(3):326–337.
- Hagino H, Narita R, Yokoyama Y, et al. A multicenter, randomized, rater-blinded, parallel-group, phase 3 study to compare the efficacy, safety, and immunogenicity of biosimilar RGB-10 and reference once-daily teriparatide in patients with osteoporosis. Osteoporos Int. 2019;30(10):2027–2037.
- Pleiner-Duxneuner J, Zwettler E, Paschalis E, et al. Treatment of osteoporosis with parathyroid hormone and teriparatide. Calcif Tissue Int. 2009;84(3):159–170.
- Takács I, Jókai E, Kováts D, et al. The first biosimilar approved for the treatment of osteoporosis: results of a comparative pharmacokinetic/pharmacodynamic study. Osteoporos Int. 2019;30(3): 675–683.
- Farmahini Farahani M, Maghzi P, Jafari Aryan N, et al. A randomized, double-blind, parallel pharmacokinetic study comparing the trastuzumab biosimilar candidate, AryoTrust®, and reference trastuzumab in healthy subjects. Expert Opin Investig Drugs. 2020;29(12):1443–1450.
- EMA. Biosimilars in the EU: information guide for healthcare professionals. European Medicines Agency 2017 [ cited 2021 Apr 24]. Available from: https://www.ema.europa.eu/en/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf
- EMA. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues: EMA; 2015. [cited 2021 Apr 24]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en-2.pdf
- EMA. Guideline on bioanalytical method validation: EMA; 2011 [cited 2021 Apr 24]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-bioanalytical-method-validation_en.pdf
- Farías J, Keller GA, Papouchado M, et al. Relative bioavailability between two teriparatide formulations in healthy volunteers. Int J Clin Pharmacol Ther. 2016;54(8):649–656.
- EMA. Guideline on the investigation of bioequivalence. European medicines agency. European Medicines Agency2016 [ cited 2021 Apr 24]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-bioequivalence-rev1_en.pdf
- Paik J, Scott LJ. Romosozumab: a review in postmenopausal osteoporosis. Drugs & Aging. 2020;37(11):845-855.
- McCamish M, Woollett G. Worldwide experience with biosimilar development. mAbs. 2011;3(2):209–217.